drugset
drugset / Trial / NCT07803744

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

NCT07803744 ↗

Phase 1 Recruiting 18 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.

Timeline

Start
2026-09-11
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide — Subcutaneous
Background Acetaminophen Small molecule — Oral

Indications

obesity disorder type 1 diabetes mellitus